Remove 2019 Remove Chronic Condition Remove Clinic Remove Provider
article thumbnail

Psychedelics – reasons for caution: Stacy Fischer, Brian Anderson, Theora Cimino

GeriPal

FDA is considering approval, shifting away from Schedule I restrictions, paving the way for use in clinical practice. Potential use in palliative care , chronic pain , and for mood disorders is tantalizing. In our prior podcast with Ira Byock on psychedelics in 2019 we talked primarily about the potential of psychedelics.

article thumbnail

Drug Pricing Reform Gathers Steam (Part 1): White House Drug Pricing Plan Offers Laundry List of Existing Democrat Priorities

FDA Law Blog

A May 2019 CMS final rule that would have required drug TV advertisements to disclose the WAC of the drug was challenged by a group of pharmaceutical companies and vacated on statutory grounds by the D.C. The Plan supports legislative action to control total drug costs and patient out-of-pocket (“OOP”) costs for Medicare Part D beneficiaries.